125I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Brachytherapy"
DOI: 10.1016/j.brachy.2021.09.001
Abstract: PURPOSE/OBJECTIVE(S) To determine if patients with unfavorable intermediate-risk (UIR), high-risk (HR), or very high-risk (VHR) prostate cancer (PCa) treated with 125I interstitial brachytherapy benefit from androgen deprivation therapy (ADT). MATERIALS/METHODS We reviewed our institutional database… read more here.
Keywords: risk; high risk; interstitial brachytherapy; pca ... See more keywords